论文部分内容阅读
作者研究了1982～1988年间新诊断的339例原发性成人急性髓细胞自血病(AML)细胞表面抗原的表达及其预后意义。AML 诊断依据FAB 标准及细胞化学结果。所有病人的治疗均采用包括DNR和Ara-C 在内的诱导缓解方案。结果:45/211例(21%)AML CD_2(T 细胞标记)阳性,41/298例(14%)有CD_(19)(B 细胞标记)表达,而在170例同时检测了CD_2和CD_(19)的AML 病例中,56例(33%)有CD_2和CD_(19)表达。虽然M_4E 和M_3中CD_2或CD_(19)阳性的病例分别是阴性病例的8倍和2倍,但其他FAB 亚型无此差别。为了解CD_2和CD_(19)阳性细胞是否属于一种“早期造血细胞”(CD_(34)阳性)或大颗粒淋巴细胞/自然杀伤细胞(CD_(16)阳性),作者分析了CD_2和CD_(19)阳性者的CD_(34)和CD_(16)的表达,作者发现CD_(34)、CD_(16)与CD_2和CD_(19)间有
The authors studied the expression and prognostic significance of 339 newly diagnosed acute adult myeloid leukemia (AML) cell surface antigens from 1982 to 1988. AML diagnosis is based on FAB criteria and cytochemical results. All patients were treated with induction mitigation including DNR and Ara-C. Results: 45/211 patients (21%) were positive for AML CD-2 (T-cell marker), 41/298 (14%) were found to have CD_(19) (B-cell marker) expression, and CD_2 and CD_ were detected in 170 patients simultaneously. In 19 cases of AML, 56 cases (33%) had CD2 and CD_(19) expression. Although the cases of CD4 or CD_(19) positive in M_4E and M_3 were 8 times and 2 times of negative cases, respectively, the other FAB subtypes did not differ. To understand whether CD2 and CD_(19) positive cells belong to an “early hematopoietic cell” (CD_ (34) positive) or large granular lymphocyte/natural killer cell (CD_ (16) positive), the authors analyzed CD_2 and CD_ ( 19) Expression of CD_(34) and CD_(16) in positive individuals. The authors found that CD_(34), CD_(16) and CD_2 and CD_(19)